Skip to content
10-Q

Quarterly Report

ACRO BIOMEDICAL CO., LTD. ACBM

0001640334-25-001281

← back to feed
Filed
Jul 23, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Jul 23, 2025 60.04M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $317.3K
Current Liabilities Q3 2024 · Dec 31, 2023 $288.58K
Total Liabilities Q3 2024 · Sep 30, 2024 $324.18K
Total Liabilities Q3 2024 · Dec 31, 2023 $315.47K
Current Assets Q3 2024 · Sep 30, 2024 $701
Current Assets Q3 2024 · Dec 31, 2023 $1.63K
Total Assets Q3 2024 · Sep 30, 2024 $38.68K
Total Assets Q3 2024 · Dec 31, 2023 $58.46K
Rd Expense Q3 2024 · Sep 30, 2024 $0
Rd Expense Q3 2024 · Sep 30, 2024 $0
Rd Expense Q3 2024 · Sep 30, 2023 $396.55K
Rd Expense Q3 2024 · Sep 30, 2023 $4.79M
Shares Diluted Q3 2024 · Sep 30, 2023 60.04M sh
Shares Diluted Q3 2024 · Sep 30, 2023 60.04M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$2.83K
Stockholders Equity Q3 2024 · Sep 30, 2023 −$239.61K
Stockholders Equity Q3 2024 · Jun 30, 2023 $339.65K
Stockholders Equity Q3 2024 · Mar 31, 2023 $410.9K
Stockholders Equity Q3 2024 · Dec 31, 2022 $486.37K
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.03
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.15
Sga Expense Q3 2024 · Sep 30, 2023 $700.15K
Sga Expense Q3 2024 · Sep 30, 2023 $3.5M
Net Income Q3 2024 · Sep 30, 2023 −$1.59M
Net Income Q3 2024 · Sep 30, 2023 −$8.79M
Net Income Q3 2024 · Jun 30, 2023 −$3.2M
Net Income Q3 2024 · Mar 31, 2023 −$4M
Operating Income Q3 2024 · Sep 30, 2023 −$1.59M
Operating Income Q3 2024 · Sep 30, 2023 −$8.79M
Revenue Q3 2024 · Sep 30, 2023 $0
Revenue Q3 2024 · Sep 30, 2023 $0